Post‐translational modifications linked to preclinical Alzheimer's disease–related pathological and cognitive changes
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.13576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Olamide Abiose und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION In this study, we leverage proteomic techniques to identify communities of proteins underlying Alzheimer's disease (AD) risk among clinically unimpaired (CU) older adults. METHODS We constructed a protein co‐expression network using 3869 cerebrospinal fluid (CSF) proteins quantified by SomaLogic, Inc., in a cohort of participants along the AD clinical spectrum. We then replicated this network in an independent cohort of CU older adults and related these modules to clinically‐relevant outcomes. RESULTS We discovered modules enriched for phosphorylation and ubiquitination that were associated with abnormal amyloid status, as well as p‐tau 181 (M4: β = 2.44, p < 0.001, M7: β = 2.57, p < 0.001) and executive function performance (M4: β = −2.00, p = 0.005, M7: β = −2.39, p < 0.001). DISCUSSION In leveraging CSF proteomic data from individuals spanning the clinical spectrum of AD, we highlight the importance of post‐translational modifications for early cognitive and pathological changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
- Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, California, USA.
- The Phil and Penny Knight Initiative for Brain Resilience, Stanford University, Stanford, California, USA.
- Department of Genetics, Stanford University, Stanford, California, USA.
- Center for Biomedical Informatics Research, Stanford University School of Medicine, Stanford, California, USA.
- Chan Zuckerberg Biohub, San Francisco, California, USA.
ORCID-Profile: Olamide Abiose
Förderung
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Abiose, O., Rutledge, J., Moran-Losada, P., Belloy, M. E., Wilson, E. N., He, Z., Trelle, A. N., Channappa, D., Romero, A., Park, J., Yutsis, M. V., Sha, S. J., Andreasson, K. I., Poston, K. L., Henderson, V. W., Wagner, A. D., Wyss-Coray, T., & Mormino, E. C. (2024). Post‐translational modifications linked to preclinical Alzheimer's disease–related pathological and cognitive changes. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13576
Vancouver
Abiose O, Rutledge J, Moran-Losada P, Belloy ME, Wilson EN, He Z, et al. Post‐translational modifications linked to preclinical Alzheimer's disease–related pathological and cognitive changes. Alzheimer's & Dementia. 2024. doi:10.1002/alz.13576
BibTeX
@article{Abiose2024,
author = {Abiose, Olamide and Rutledge, Jarod and Moran-Losada, Patricia and Belloy, Michael E and Wilson, Edward N and He, Zihuai and Trelle, Alexandra N and Channappa, Divya and Romero, America and Park, Jennifer and Yutsis, Maya V and Sha, Sharon J and Andreasson, Katrin I and Poston, Kathleen L and Henderson, Victor W and Wagner, Anthony D and Wyss-Coray, Tony and Mormino, Elizabeth C},
title = {Post‐translational modifications linked to preclinical Alzheimer's disease–related pathological and cognitive changes},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.13576}
}
EUVIMED